JP5473328B2 - ウイルス感染の予防および治療用の薬剤の製造のためのヒドロキシ安息香酸エステルおよび類似体の使用 - Google Patents

ウイルス感染の予防および治療用の薬剤の製造のためのヒドロキシ安息香酸エステルおよび類似体の使用 Download PDF

Info

Publication number
JP5473328B2
JP5473328B2 JP2008524341A JP2008524341A JP5473328B2 JP 5473328 B2 JP5473328 B2 JP 5473328B2 JP 2008524341 A JP2008524341 A JP 2008524341A JP 2008524341 A JP2008524341 A JP 2008524341A JP 5473328 B2 JP5473328 B2 JP 5473328B2
Authority
JP
Japan
Prior art keywords
treatment
prevention
acid ester
hpv
hydroxybenzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2008524341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502985A (ja
JP2009502985A5 (enExample
Inventor
ウエイホア チン，
Original Assignee
ションホア （グアーンジョウ） ファーマスーティカル サイエンス アンド テクノロジー カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ションホア （グアーンジョウ） ファーマスーティカル サイエンス アンド テクノロジー カンパニー リミテッド filed Critical ションホア （グアーンジョウ） ファーマスーティカル サイエンス アンド テクノロジー カンパニー リミテッド
Publication of JP2009502985A publication Critical patent/JP2009502985A/ja
Publication of JP2009502985A5 publication Critical patent/JP2009502985A5/ja
Application granted granted Critical
Publication of JP5473328B2 publication Critical patent/JP5473328B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
JP2008524341A 2005-08-02 2006-07-21 ウイルス感染の予防および治療用の薬剤の製造のためのヒドロキシ安息香酸エステルおよび類似体の使用 Expired - Lifetime JP5473328B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB2005100122870A CN100427082C (zh) 2005-08-02 2005-08-02 羟基苯甲酸酯及其类似物在制备预防和治疗病毒性感染药物中的应用
CN200510012287.0 2005-08-02
PCT/CN2006/001792 WO2007014515A1 (en) 2005-08-02 2006-07-21 Use of hydroxybenzoic acid ester and analogues for the manufacture of a mendicament for the prevention and treatment of virus infection

Publications (3)

Publication Number Publication Date
JP2009502985A JP2009502985A (ja) 2009-01-29
JP2009502985A5 JP2009502985A5 (enExample) 2009-09-03
JP5473328B2 true JP5473328B2 (ja) 2014-04-16

Family

ID=37698614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524341A Expired - Lifetime JP5473328B2 (ja) 2005-08-02 2006-07-21 ウイルス感染の予防および治療用の薬剤の製造のためのヒドロキシ安息香酸エステルおよび類似体の使用

Country Status (21)

Country Link
EP (1) EP1930002B1 (enExample)
JP (1) JP5473328B2 (enExample)
KR (1) KR100922605B1 (enExample)
CN (1) CN100427082C (enExample)
AP (1) AP2658A (enExample)
AU (1) AU2006275232B2 (enExample)
BR (1) BRPI0616536B8 (enExample)
CA (1) CA2617659C (enExample)
CY (1) CY1117480T1 (enExample)
DK (1) DK1930002T3 (enExample)
EA (1) EA016576B1 (enExample)
ES (1) ES2567130T3 (enExample)
HU (1) HUE027244T2 (enExample)
IL (1) IL189162A (enExample)
MX (1) MX2008001673A (enExample)
NZ (1) NZ566153A (enExample)
PL (1) PL1930002T3 (enExample)
SI (1) SI1930002T1 (enExample)
UA (1) UA90159C2 (enExample)
WO (1) WO2007014515A1 (enExample)
ZA (1) ZA200801635B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603522B (zh) * 2011-01-23 2015-04-22 复旦大学 苯酚类衍生物及其在制备抗乙肝病毒药物中的用途
KR101401154B1 (ko) * 2011-02-22 2014-05-30 경희대학교 산학협력단 메틸 갈레이트를 포함하는 조절 ｔ 세포 활성 억제용 약학적 조성물
PL404138A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
CN103599093B (zh) 2013-11-18 2016-06-01 中国医学科学院生物医学工程研究所 一种抗hpv药物制剂及用途
CN103948729B (zh) * 2014-05-15 2015-09-09 陈欣 一种治疗宫颈糜烂的中药栓剂及其制备方法
CA3008466C (en) 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
EP3395355B1 (en) * 2015-12-18 2026-03-04 Talengen International Limited Plasminogen for use in treating cervical erosion
CN105748506B (zh) * 2016-03-03 2018-08-17 青岛海洋生物医药研究院股份有限公司 褐藻酸硫酸酯在制备预防和治疗由人乳头瘤状病毒引起的疾病的药物和保健品中的应用
JPWO2019087884A1 (ja) * 2017-10-31 2020-11-19 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
JPWO2019087881A1 (ja) * 2017-10-31 2020-10-22 富士フイルム株式会社 抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
JPWO2019087888A1 (ja) * 2017-10-31 2020-11-12 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
CN111419833B (zh) * 2020-06-02 2023-04-07 上海爱启医药技术有限公司 没食子酸的药物应用
CN114146078B (zh) * 2020-09-07 2025-09-16 盈科瑞（横琴）药物研究院有限公司 对羟基苯甲酸乙酯抗冠状病毒感染的应用
CN114146082B (zh) * 2020-09-07 2025-09-05 盈科瑞（横琴）药物研究院有限公司 对羟基苯甲酸甲酯及其钠盐抗冠状病毒的用途
CN112375803B (zh) * 2020-11-16 2024-05-07 石河子大学 五倍子中抗炎活性成分没食子酸乙酯的筛选方法及其用途
CN118489806A (zh) * 2024-05-13 2024-08-16 浙江大学 多酚在制备预防和/或缓解动物锌过载所致肠道免疫应激或肠道损伤制剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929985A (en) * 1974-01-18 1975-12-30 Richardson Merrell Inc Anhydrous candicidin foam compositions
JPS62132824A (ja) * 1985-12-05 1987-06-16 Eisai Co Ltd 肝炎への治療剤
SE464167B (sv) * 1989-07-31 1991-03-18 Analytecon Sa Topisk farmaceutisk beredning av podophyllotoxin
CN1042298C (zh) * 1989-07-31 1999-03-03 安纳利蒂康有限公司 含鬼臼毒的乳膏形式的药物组合物的制备方法
CN1068782A (zh) * 1992-01-30 1993-02-10 展静 轮胎气压报警装置
NL9500216A (nl) * 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Farmaceutische samenstelling voor de behandeling van herpes.
DE19514694A1 (de) * 1995-04-13 1996-10-17 Ina Dr Levi Breitspektrum-Antiinfektivamittel
JPH0959151A (ja) * 1995-08-24 1997-03-04 Kao Corp ＮＦ−κＢ活性化抑制剤
CN1068782C (zh) * 1996-04-18 2001-07-25 中国医药研究开发中心 以栾树提取物为有效组分的抗癌药物及制备方法
JPH09328404A (ja) * 1996-06-07 1997-12-22 Iwao Hishida 殺菌、抗菌および不活化剤
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
KR20010013377A (ko) 1997-06-04 2001-02-26 데이비드 엠 모이어 마일드한 잔류성 항균 조성물
DK1383512T3 (da) * 2001-05-03 2004-11-15 Farmigea Spa Anvendelse af sucralfat til behandling af cervikal erosion

Also Published As

Publication number Publication date
ES2567130T3 (es) 2016-04-20
KR100922605B1 (ko) 2009-10-21
EA200800467A1 (ru) 2008-10-30
HK1113747A1 (en) 2008-10-17
IL189162A0 (en) 2008-08-07
SI1930002T1 (sl) 2016-06-30
BRPI0616536A2 (pt) 2012-12-25
CY1117480T1 (el) 2017-04-26
WO2007014515A1 (en) 2007-02-08
BRPI0616536B8 (pt) 2021-05-25
HUE027244T2 (en) 2016-09-28
CA2617659A1 (en) 2007-02-08
AU2006275232B2 (en) 2010-12-02
BRPI0616536B1 (pt) 2020-05-26
MX2008001673A (es) 2008-11-06
EA016576B1 (ru) 2012-06-29
DK1930002T3 (en) 2016-04-11
PL1930002T3 (pl) 2016-07-29
EP1930002A1 (en) 2008-06-11
CN1907276A (zh) 2007-02-07
NZ566153A (en) 2011-07-29
KR20080036128A (ko) 2008-04-24
ZA200801635B (en) 2009-06-24
JP2009502985A (ja) 2009-01-29
CN100427082C (zh) 2008-10-22
UA90159C2 (ru) 2010-04-12
EP1930002A4 (en) 2010-04-21
AP2658A (en) 2013-05-09
AU2006275232A1 (en) 2007-02-08
IL189162A (en) 2014-04-30
CA2617659C (en) 2013-02-26
EP1930002B1 (en) 2016-01-06

Similar Documents

Publication Publication Date Title
IL189162A (en) Use of a hydroxybenzoic acid ester and its analogs with at least 3 oh transducers to produce a drug to prevent and treat the HPV virus infection
US9782426B2 (en) Anti-viral therapeutic composition
CN102670588B (zh) 鞣花酸用于制备抗病毒药物的应用
RU2361867C2 (ru) Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина
JP2019510814A (ja) アルギン酸硫酸エステルおよびヒトパピローマウイルスによる疾患の予防および治療する薬物と健康食品の製造におけるその使用
CN110025717A (zh) 知母皂苷酶解转化物在制备抑制皮肤浅表真菌药物中的应用
CN1245972C (zh) 柚皮素及其盐用于制备止咳化痰药物
JP2009502985A5 (enExample)
JP2021525263A (ja) 処置
US8044098B2 (en) Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection
CN101342166B (zh) 羟基苯甲酸酯及其类似物在制备预防和治疗乙型肝炎病毒的药物中的应用
CN100428930C (zh) 对羟基苯甲酸及其类似物在制备预防和治疗皮肤黏膜病毒性感染药物中的应用
US20210196676A1 (en) Treatment of viral infections and virally associated lesions with sequiterpene lactones
CN1299753C (zh) 一种中药组合物及其制备方法和质量控制方法
CN106177900A (zh) 一种抗人乳头瘤病毒的凝胶及其制备方法
HK1113747B (en) Use of hydroxybenzoic acid ester compounds for the manufacture of a medicament for the prevention and treatment of hpv infection
JPH10175852A5 (enExample)
JP4899002B2 (ja) 抗原虫剤
WO2019104587A1 (zh) 一种药物组合物及其用途
CN103893280B (zh) 拳参提取物在制备抗病毒药物中的应用及其提取方法
EP3241555A1 (en) Use of pyrophosphate ion analogues for the treatment of hpv infection
CN101301299A (zh) 药物组合物及其在制备抗微生物药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120709

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130806

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140204

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5473328

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250